The first patient with Paget's disease has been treated by the PAGETEX clinical protocol.
The PAGETEX study aims to treat people with Paget's disease extra-breast vulva by photodynamic therapy. A new medical device using light emitting fabric (LEF) technology is currently being tested in the Dermatology Department of Lille University Hospital.
A maximum of 24 patients will be enrolled in this phase II study, which aims to evaluate a disease control rate at 3 months (total and partial response) in 30% of patients included.
This clinical study is supported by the iLatext project, funded by the ERDF under the ERDF-ESF operational program.
Four members of the OncoThAI research team involved in the PAGETEX protocol (from left to right): Dr. Cyril MAIRE (Dermatologist), Fabienne LECOMTE (Clinical research assistant), Laurine ZIANE (Engineer and future PhD student) et Elise THECUA (PhD student, CIFRE contract with the company MDB TEXINOV).
